Tecan will manufacture and deliver ML instruments for Enigma's global market supplies for an initial five-year contract and will also manage the ML instruments supply chain.
The first ML demonstration instruments have been delivered for Enigma's Glaxosmithkline delivery commitments for point-of-care molecular-diagnostic influenza tests.
The launch of Enigma ML and the supply of commercial systems to identify specific influenza virus strains are anticipated in Q4 2010, subject to successful clinical trials and regulatory approval.
Enigma will also add additional tests, such as for infectious-disease management, to the ML system test-menu in the future.
